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for Fosamax, Actonel, and Protelos, and from the European label
for Bonviva. Costs of fractures were taken from the NICE review
of Protelos and costs of the medications were taken from the
MIMS listing from February, 2007. Utilities were obtained from
the literature (Kanis, OI 2004;15:20–6). RESULTS: For patients
50 and older, zoledronic acid 5 mg dominated (i.e., more effective
at lower cost) branded Fosamax, Actonel, and Protelos. For
patients 70 and older, zoledronic acid 5 mg dominated Bonviva
while at lower ages, it was more cost effective (ICER < 3,100/
QALY gained). Incremental cost effectiveness ratios against
calcium plus vitamin D for zoledronic acid 5 mg were around or
below the usually referenced threshold of 20 K/QALY, ranging
from 20,582/QALY at age 50 to 7,418/QALY at age 80.
For the other treatments, the ranges of ICER versus calcium
plus vitamin D were 36,095/QALY to 12,542/QALY for
Fosamax, 53,916/QALY to 22,261/QALY for Actonel,
50,840/QALY to 26,179/QALY for Protelos, and 158,479/
QALY to 57,583/QALY for Bonviva. CONCLUSION: For
patients aged 50 and above with a BMD T-score of -2.5,
zoledronic acid 5 mg either dominates or is cost-effective com-
pared with Fosamax, Actonel, Protelos, and Bonviva.
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OBJECTIVES: The purpose of the study was to assess the cost-
effectiveness of the recombinant human PTH (1–34) (teri-
paratide) (Forsteo, Eli Lilly) and recombinant human PTH
(1–84) (Preotact, Nycomed) in subjects with similar clinical
characteristics to patients with osteoporosis in normal Swedish
clinical practice. METHODS: The cost-effectiveness was esti-
mated in an existing Markov cohort osteoporosis model using
6-month cycles and a lifetime horizon. The model was popu-
lated with Swedish epidemiological and economic data. To
reﬂect the normal clinical practice, the simulated subjects cor-
responded to the Swedish cohort in the European Forsteo
Observational Study (EFOS) (mean age 72 years, total hip
T-score -2.7, 3.5 prevalent vertebral fractures). The cost per
QALY gained of both teriparatide and PTH (1–84) was esti-
mated compared to no treatment based on efﬁcacy estimates
from phase III pivotal clinical trials of each drug. For teri-
paratide, the risk reduction for new vertebral fractures was
65% and for non-vertebral fragility fractures 53%, while PTH
(1–84) reduced the risk of vertebral fractures by 58% and
showed no difference in non-vertebral fracture risk reduction.
An indirect cost-effectiveness comparison between the two regi-
mens was also attempted. The annual drug cost of teriparatide
and PTH (1–84) in Sweden was €5241 and €4643, respectively.
Both treatment regimens were assumed to be given for 18
months per local reimbursement guidelines. The analysis took a
societal perspective excluding costs in added life years in the
base estimations. RESULTS: In the base case analysis excluding
the impact of hypercalcaemia the cost per QALY gained with
teriparatide and PTH (1–84) vs. no treatment was estimated at
€47,811 and €125,474, respectively. An indirect comparison
between the two treatments indicated teriparatide to be a domi-
nating alternative. CONCLUSION: This study suggests that,
based on the efﬁcacy estimates from pivotal clinical trials and
the Swedish cost of both drugs, teriparatide is a more cost-
effective treatment option than PTH (1–84).
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OBJECTIVES: To estimate the economic burden of patients with
osteoporotic hip fracture amongKoreanwomen.METHODS:All
claims records of Korean National Health Insurance for women
50 years of age or older with a diagnosis of hip fracture from 2002
to 2004 were identiﬁed. The ﬁrst 6-month period was set to be a
‘window period,’ such that patients were deﬁned as incident cases
if their ﬁrst record of fracture visit or admissionwas observed after
June 30, 2002. We excluded patients with multiple fractures,
patients with the records of high-cost diseases, such as cancer, and
patients without a record of a diagnosis or prescription for
osteoporosis. For each patient, we cumulated the claims amount
of the ﬁrst fracture visit or admission and follow-up treatments for
2 years after the incidence of fracture. Also, to investigate out-of-
pocket costs outside the health care institutions, face-to-face
interviews were conducted with 101 patients from 4 general
hospitals who had experienced a hip fracture at least 6 months
before the time of the interview. The total cost for fracture was the
sum of the direct health care costs, transportation costs for visits
to hospitals, and caregivers’ time cost spent hospital or outpatient
visits. RESULTS: A total of 22,247 osteoporotic hip fracture
patients were identiﬁed during 2.5 years. For the ﬁrst year of
fracture, patients had an average of 3.28 visits and 0.97 admis-
sions, whereas 0.35 visits and 0.02 admissions were recorded for
the second year. The 2-year cost was US$8,538 and increased
exponentially with age, $7,616 for 50–64 years old, $9,542 for
65–74, $10,077 for 75–84, and $10,118 for 85 or above. CON-
CLUSION: Exploring the economic burden of osteoporotic hip
fracture will motivate policy makers and clinicians to adopt
effective treatment options for osteoporosis to prevent the inci-
dence of fracture among elderly population.
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OBJECTIVES: To estimate hospital and facility costs resulting
from falls in long term care facilities (LTCFs). METHODS: The
study employed a non-randomized, before and after with com-
parison group design. Propensity scoring and matching were
used to control for baseline differences between fallers and non-
fallers. A multi-facility long-term care company provided data
from residents institutionalized between January 1, 2002 and
October 30, 2004. Data included Minimum Data Set (MDS)
observations, Resource Utilization Group (RUG) classiﬁcations,
and demographics. An index date was assigned to each resident
to identify pre-and post-periods. The index date was deﬁned as
the date of the ﬁrst fall for fallers. The index date was assigned to
non-fallers such that the time in the pre-period was equal for
fallers and non-fallers. Hospital costs were estimated from MDS
measures of the numbers of hospitalizations in each period and a
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